Is diltiazem an appropriate treatment for stable supraventricular tachycardia (SVT) in adults?

Yes, diltiazem is highly effective for treating stable SVT in adults.

Intravenous diltiazem is a Class IIa recommendation (can be effective) for acute treatment of hemodynamically stable SVT, with conversion rates of 64-98%, and is particularly useful when adenosine fails or is contraindicated 1.

Acute Treatment Algorithm

First-Line Approach

• Start with vagal maneuvers (Valsalva, carotid massage) in all stable patients
• Adenosine remains the preferred first-line pharmacologic agent (Class I recommendation) with ~95% conversion rate 1

When to Use Diltiazem Instead

Diltiazem is particularly appropriate when:

• Adenosine has failed to convert SVT (diltiazem successfully rescues 35% of adenosine failures) 2
• Patient cannot tolerate adenosine or experiences recurrence after adenosine conversion 1
• Patient has contraindications to beta blockers 1
• SVT converts to atrial fibrillation/flutter (diltiazem controls ventricular rate in 77% of cases) 2

Dosing and Administration

IV Diltiazem Protocol:

• Initial dose: 0.25 mg/kg IV bolus over 2 minutes 3, 4
• If unsuccessful: Second dose of 0.35 mg/kg after 15 minutes 4
• Alternative: Slow infusion at 2.5 mg/min up to 50 mg total dose (reduces hypotension risk) 5, 6
• Conversion typically occurs within 2-5 minutes of administration 3, 4

Efficacy Data

The evidence strongly supports diltiazem's effectiveness:

• Conversion rate: 90-98% in clinical trials 1, 4, 6
• Superior to esmolol (100% vs 25% conversion rate) 7
• Comparable to adenosine in recent comparative studies (82.4% vs 66.8%, though not statistically significant) 2
• Slower time to conversion than adenosine (median 6 minutes vs 3 minutes) but higher overall success 2

Critical Safety Contraindications

DO NOT use diltiazem if:

• Hemodynamically unstable (hypotension, shock, altered mental status, acute heart failure) - use synchronized cardioversion instead 1
• Suspected systolic heart failure or reduced ejection fraction 1
• Wide-complex tachycardia or suspected ventricular tachycardia (can cause hemodynamic collapse) 1
• Pre-excited atrial fibrillation/WPW with anterograde accessory pathway conduction (can accelerate ventricular rate → ventricular fibrillation) 1
• Concurrent IV beta blocker use (risk of severe bradycardia/heart block)

Common Pitfalls to Avoid

1. Rhythm misidentification: Always confirm narrow-complex regular tachycardia before administering. If QRS >120ms or irregular, consider alternative diagnoses 1

2. Hypotension risk: While rare with slow infusion (0.98% incidence), rapid bolus can cause hypotension. Slow infusion over 20 minutes significantly reduces this risk 1, 5, 6

3. Pre-excitation: Check for delta waves on prior ECGs. In WPW with AF, diltiazem blocks the AV node, forcing conduction down the accessory pathway and potentially causing ventricular fibrillation 1

4. Heart failure: Even in "stable" patients, diltiazem's negative inotropic effects can precipitate decompensation in those with underlying systolic dysfunction 1, 3

Ongoing Management

For patients declining or not candidates for catheter ablation:

• Oral diltiazem or verapamil is Class I recommendation for ongoing SVT prevention 1
• Well-tolerated with proven efficacy in reducing episode frequency and duration 1
• Monitor for bradyarrhythmias and hypotension when initiating therapy 1

Mechanism of Action

Diltiazem works by slowing AV nodal conduction and prolonging AV nodal refractoriness, interrupting the reentry circuit in AVNRT and AVRT 3. It exhibits frequency-dependent effects, selectively reducing heart rate during tachycardia with minimal effect at normal rates 3. Importantly, it has no effect on accessory pathway conduction 4, which is why it's safe in orthodromic AVRT but dangerous in antidromic or pre-excited AF.